Oct. 30, 2012 | Vol. 11 No. 213 | Full Issue in PDF Format
View the entire issue.
UCB plans to submit marketing applications for Cimzia in psoriatic arthritis and axial spondyloarthritis (AxSpA), including ankylosing spondylitis, to the FDA and EU by the end of the year.
Bayer HealthCare and Onyx Pharmaceuticals have won priority review for Stivarga to treat metastatic and/or unresectable gastrointestinal stromal tumors (GIST).
Par Pharmaceutical can launch a generic version of AstraZeneca’s extend-release antipsychotic Seroquel XR by November 2016 following its acquisition of Handa Pharmaceuticals’ ANDA.
Titan Pharmaceutical has submitted an NDA seeking priority review of its Probuphine subcutaneous implant to treat adult opioid dependence.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.